Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

BACKGROUND: The combination of Programmed Cell Death 1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) blockade has dramatically improved the overall survival rate for malignant melanoma. Immune checkpoint blockers (ICBs) limit the tumor’s immune escape yet only for approximately a third of all...

Descripción completa

Detalles Bibliográficos
Autores principales: Amaro, Adriana, Reggiani, Francesco, Fenoglio, Daniela, Gangemi, Rosaria, Tosi, Anna, Parodi, Alessia, Banelli, Barbara, Rigo, Valentina, Mastracci, Luca, Grillo, Federica, Cereghetti, Alessandra, Tastanova, Aizhan, Ghosh, Adhideb, Sallustio, Fabio, Emionite, Laura, Daga, Antonio, Altosole, Tiziana, Filaci, Gilberto, Rosato, Antonio, Levesque, Mitchell, Maio, Michele, Pfeffer, Ulrich, Croce, Michela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024396/
https://www.ncbi.nlm.nih.gov/pubmed/36934257
http://dx.doi.org/10.1186/s13046-023-02628-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024396/
https://www.ncbi.nlm.nih.gov/pubmed/36934257
http://dx.doi.org/10.1186/s13046-023-02628-x

Ejemplares similares